Monitor the special meeting vote on November 4, 2026. Approval is highly likely given insider control (~82% of shares held by officers/directors). Post-approval, watch for the filing of the charter amendment and subsequent conversion of preferred shares, which would add ~108.96M shares to the float. Also track any additional ATM sales under the $354.3M remaining program.
Price Chart
Executive Summary
Summit Therapeutics is holding a special meeting on November 4, 2026, to approve a charter amendment increasing authorized common shares from 1,000,000,000 to 2,000,000,000. The increase is required to satisfy a contractual obligation under a $2.0 billion private placement with AstraZeneca Holdings B.V., which closed on October 5, 2026, and issued convertible preferred shares exchangeable for 108,955,369 common shares. Failure to approve would trigger a costly redemption of the preferred shares and could impair the company's ability to raise capital.
Key Facts
- Proposal to increase authorized common shares from 1,000,000,000 to 2,000,000,000.
- As of October 1, 2026, there were 799,726,418 shares outstanding and only 66,727,073 authorized unreserved shares available.
- On September 28, 2026, Summit entered a securities purchase agreement with AstraZeneca Holdings B.V. for $2.0 billion in gross proceeds via 108,955.3686 shares of Class A Convertible Preferred Stock at $18,356.14 per share.
- Each preferred share converts into 1,000 common shares, totaling 108,955,369 common shares upon conversion.
- The charter amendment must be effective by December 31, 2026, per the purchase agreement; if not effective by April 5, 2028, the preferred shares become redeemable for cash at market value.
- CEO Robert W. Duggan beneficially owns 71.8% of common stock; combined with spouse Dr. Zanganeh (7.3%), the couple controls ~79.1%.
- All executive officers and directors as a group beneficially own 81.8% of outstanding shares.
- The board unanimously recommends a vote FOR the proposal.
Financial Impact
Authorized share count doubling from 1B to 2B; $2.0B private placement closed; up to $354.3M remaining under ATM program; potential dilution of up to 108.96M shares upon conversion of preferred stock.
Risk Factors
- If the proposal fails, the company would breach its contractual obligation to AstraZeneca, potentially triggering a costly cash redemption of preferred shares.
- Failure to approve could impair the company's ability to raise capital and negatively affect its ability to continue as a going concern.
- Future issuances of common stock (including upon conversion of preferred shares) will dilute existing shareholders' voting power and earnings per share.
- The authorized share increase could be used as an anti-takeover measure, though the board states it is not intended for that purpose.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEF 14A Filing (Primary) | 0001193125-26-424642 |
| Document: 0001193125-26-424642-index-headers.html | 0001193125-26-424642 |
| Document: 0001193125-26-424642-index.html | 0001193125-26-424642 |
| Document: 0001193125-26-424642.txt | 0001193125-26-424642 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | Press Release | $15.83 $15.55 | ▼ −1.77% | ▼ −0.59% | $14.50 (−8.40%) |
Oct 19, 2026 7d ago | DEF 14A | $15.57 $16.09 | ▲ +3.34% | ▲ +3.00% | $14.50 (−6.87%) |
Sep 28, 2026 28d ago | 8-K | $16.39 $16.91 | ▲ +3.17% | ▲ +3.38% | $14.50 (−11.53%) |
Sep 15, 2026 5w ago | 8-K | $17.40 $17.54 | ▲ +0.80% | ▲ +0.48% | $14.50 (−16.67%) |
Sep 14, 2026 6w ago | 8-K | $18.42 $17.40 | ▼ −5.54% | ▼ −5.08% | $14.50 (−21.28%) |
Sep 3, 2026 7w ago | 8-K | $17.13 $17.61 | ▲ +2.77% | ▲ +3.16% | $14.50 (−15.35%) |
Aug 26, 2026 8w ago | 8-K | $14.23 $14.33 | ▲ +0.70% | ▲ +0.05% | $14.50 (+1.90%) |
Aug 5, 2026 11w ago | 8-K | $13.53 $13.54 | ▲ +0.07% | ▲ +0.23% | $14.50 (+7.17%) |
Jul 22, 2026 13w ago | 8-K | $14.74 $14.98 | ▲ +1.63% | ▲ +2.86% | $14.50 (−1.63%) |
Jun 12, 2026 19w ago | Insider Cluster | $14.01 $14.13 | ▲ +0.86% | ▼ −0.91% | $14.50 (+3.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers